Bio & Pharma
S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
The biotech company will adopt a candidate substance from a Swiss pharmaceutical company
By Dec 14, 2022 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Macquarie Korea Asset Management confirms two nominees
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Korea's Taeyoung to sell local hotel to speed up debt workout
Meritz leaves door open for an M&A, to stay shareholder friendly
South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swiss pharmaceutical company.
SillaJen plans to expedite clinical development and promote technology transfer.
SillaJen CEO Kim Jae-kyung on Tuesday told a news conference at Korea Press Center in Seoul, "Three clinical institutions in the US this month will start recruiting patients for Phase 1 clinical trials of BAL0891," adding, "We will quickly conduct Phase 1 to fill the unmet demand for new anti-cancer drugs."
The company plans to hold clinical trials for intractable carcinomas such as those of triple-negative breast cancer and expand indications to other carcinomas such as those of blood cancer. BAL0891, a candidate substance for suppressing mitotic checkpoints, was introduced by SillaJen from Basilia Pharmaceutica International of Switzerland; the Korean company also has an exclusive license for use of the substance.
Preclinical studies have shown that BAL0891 effectively inhibits an array of cancer cells including those of triple-negative breast, endometrial, colorectal, urothelial, gastric and kidney cancer. Intravenous administration of the drug instead of oral also proved more effective against cancer.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Korean stock marketSamyang tops Korean ramen makers by market cap, beating Nongshim
May 17, 2024 (Gmt+09:00)
-
Corporate strategyHanwha Ocean to adopt Kyocera founder Inamori’s amoeba management
May 17, 2024 (Gmt+09:00)
Comment 0
LOG IN